Compare FTAI & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTAI | INSM |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | 985 | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 23.0B |
| IPO Year | N/A | 2000 |
| Metric | FTAI | INSM |
|---|---|---|
| Price | $250.17 | $104.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 24 |
| Target Price | ★ $274.67 | $201.17 |
| AVG Volume (30 Days) | 1.0M | ★ 4.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.73 | $182.31 |
| Revenue Next Year | $51.41 | $65.19 |
| P/E Ratio | $65.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $109.90 | $70.57 |
| 52 Week High | $323.51 | $212.75 |
| Indicator | FTAI | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 34.33 |
| Support Level | $216.34 | $98.90 |
| Resistance Level | $261.25 | $166.81 |
| Average True Range (ATR) | 13.61 | 3.90 |
| MACD | -0.10 | 0.78 |
| Stochastic Oscillator | 75.24 | 25.88 |
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.